Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Plerixafor - Sanofi Genzyme

Drug Profile

Plerixafor - Sanofi Genzyme

Alternative Names: AMD 3100; JM 3100; Mozobil; Plerixafor-hydrochloride; SDZ SID 791

Latest Information Update: 07 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genzyme Corporation; Rega Institute for Medical Research
  • Developer Dana-Farber Cancer Institute; Memorial Sloan-Kettering Cancer Center; Sanofi; Sanofi Genzyme
  • Class Antineoplastics; Heterocyclic compounds; Polyamines; Small molecules
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stem cell mobilisation
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Stem cell mobilisation
  • Phase II Glioma
  • Phase I/II Acute myeloid leukaemia; Multiple myeloma
  • No development reported Chronic lymphocytic leukaemia; Myocardial infarction; Sickle cell anaemia
  • Discontinued HIV infections; Rheumatoid arthritis

Most Recent Events

  • 14 Dec 2018 Sanofi and CCTU- Cancer Theme completes the phase I CAM-PLEX trial for Pancreatic, Ovarian and Colorectal adenocarcinomas in United Kingdom (NCT02179970)
  • 04 Dec 2018 Phase-II clinical trials in Glioma (Combination therapy, Late-stage disease) in USA (IV) (NCT03746080)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top